PAP
FBRX

Persistent Asset Partners’s Forte Biosciences FBRX Stock Holding History

Persistent Asset Partners’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$388K Buy
18,263
+11,519
+171% +$273K 0.12% 143
2026
Q1 		$175K Sell
6,744
-3,402
-34% -$98K 0.07% 207
2025
Q4 		$277K Buy
+10,146
New +$178K 0.12% 188

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Persistent Asset Partners's FBRX Position: Q2 2026 in Review

Persistent Asset Partners increased its Forte Biosciences (FBRX) stake by 171% in Q2 2026, buying an estimated $273K and bringing the position to 18,263 shares worth $388K. The position accounts for 0.12% of the portfolio, ranked #143.

Persistent Asset Partners first reported a position in FBRX in Q4 2025 and has held it in 3 quarters since. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Persistent Asset Partners held 18,263 shares of Forte Biosciences worth $388K as of Q2 2026.
  • Persistent Asset Partners bought 11,519 Forte Biosciences shares in Q2 2026, an estimated $273K.
  • Forte Biosciences made up 0.12% of Persistent Asset Partners's portfolio in Q2 2026, its #143 holding.
  • Persistent Asset Partners first reported a position in Forte Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.